Published in Nat Med on February 17, 2008
Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell (2009) 5.91
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 4.23
Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 2.71
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 2.53
Fluid forces control endothelial sprouting. Proc Natl Acad Sci U S A (2011) 2.09
Time-lapse imaging of disease progression in deep brain areas using fluorescence microendoscopy. Nat Med (2011) 1.99
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies. Nat Rev Cancer (2009) 1.95
Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci U S A (2011) 1.88
Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol (2009) 1.87
Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A (2013) 1.83
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell (2011) 1.77
Imaging angiogenesis and the microenvironment. APMIS (2008) 1.77
Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression. J Natl Cancer Inst (2013) 1.69
Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med (2012) 1.66
Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. J Clin Invest (2009) 1.56
Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. Nat Rev Clin Oncol (2009) 1.43
Simultaneous imaging of tumor oxygenation and microvascular permeability using Overhauser enhanced MRI. Proc Natl Acad Sci U S A (2009) 1.18
Intravital imaging of stromal cell dynamics in tumors. Curr Opin Genet Dev (2009) 1.16
Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. Cancer Res (2009) 1.13
Endothelial cell metabolism in normal and diseased vasculature. Circ Res (2015) 1.09
Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol (2010) 0.99
Gasotransmitters in cancer: from pathophysiology to experimental therapy. Nat Rev Drug Discov (2015) 0.96
Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arterioscler Thromb Vasc Biol (2008) 0.94
Line-scanning particle image velocimetry: an optical approach for quantifying a wide range of blood flow speeds in live animals. PLoS One (2012) 0.93
Lymphatic function and immune regulation in health and disease. Lymphat Res Biol (2013) 0.89
Lymphatic vessels in health and disease. Wiley Interdiscip Rev Syst Biol Med (2012) 0.88
Arginine dependence of tumor cells: targeting a chink in cancer's armor. Oncogene (2016) 0.86
Proteomics-based metabolic modeling reveals that fatty acid oxidation (FAO) controls endothelial cell (EC) permeability. Mol Cell Proteomics (2015) 0.85
SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers. Mol Cell Proteomics (2013) 0.84
Roles of tetrahydrobiopterin in promoting tumor angiogenesis. Am J Pathol (2010) 0.82
NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth Delay. Cancer Res (2015) 0.81
Co-expression of endothelial and neuronal nitric oxide synthases in the developing vasculatures of the human fetal eye. Graefes Arch Clin Exp Ophthalmol (2012) 0.79
Suppression of glioma progression by Egln3. PLoS One (2012) 0.78
Development of individualized anti-metastasis strategies by engineering nanomedicines. Chem Soc Rev (2015) 0.77
Emerging trends in the pathophysiology of lymphatic contractile function. Semin Cell Dev Biol (2015) 0.77
The implications of hyponitroxia in cancer. Transl Oncol (2014) 0.76
Quantitative model for efficient temporal targeting of tumor cells and neovasculature. Comput Math Methods Med (2011) 0.75
Measuring Vascular Permeability In Vivo. Methods Mol Biol (2016) 0.75
Generation of nitric oxide gradients in microfluidic devices for cell culture using spatially controlled chemical reactions. Biomicrofluidics (2013) 0.75
A cerebellar window for intravital imaging of normal and disease states in mice. Nat Protoc (2017) 0.75
Similarities in the Metabolic Reprogramming of Immune System and Endothelium. Front Immunol (2017) 0.75
Exercise-dependent regulation of the tumour microenvironment. Nat Rev Cancer (2017) 0.75
Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 13.36
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 12.52
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 8.78
Photodynamic therapy for cancer. Nat Rev Cancer (2003) 8.00
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 5.65
Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 5.64
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov (2011) 5.59
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med (2003) 5.50
Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med (2009) 5.41
Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (2002) 5.32
Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol (2002) 5.04
Evolving functions of endothelial cells in inflammation. Nat Rev Immunol (2007) 4.94
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 4.84
Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res (2007) 4.72
Nitric oxide synthases: regulation and function. Eur Heart J (2011) 4.71
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell (2006) 4.55
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol (2009) 4.54
Tissue engineering: creation of long-lasting blood vessels. Nature (2004) 4.50
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J (2008) 4.49
Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer (2002) 3.96
Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated angiogenesis. J Clin Invest (2005) 3.95
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med (2009) 3.85
Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet (2013) 3.83
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol (2013) 3.81
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. Microvasc Res (2007) 3.64
Pathology: cancer cells compress intratumour vessels. Nature (2004) 3.60
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 3.40
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol (2006) 3.37
Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci U S A (2011) 3.34
BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov (2011) 3.34
Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J (2002) 3.25
Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics (2005) 3.24
Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys (2002) 3.21
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med (2005) 3.19
Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood (2008) 3.13
The role of nitric oxide in tumour progression. Nat Rev Cancer (2006) 3.08
Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci U S A (2008) 3.03
Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol (2009) 3.02
Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res (2002) 3.01
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res (2009) 3.00
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res (2013) 2.98
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. Am J Kidney Dis (2013) 2.89
Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med (2002) 2.81
Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci U S A (2005) 2.81
Response criteria for glioma. Nat Clin Pract Oncol (2008) 2.69
Engineering vascularized tissue. Nat Biotechnol (2005) 2.69
Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem (2007) 2.67
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol (2007) 2.65
Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell (2013) 2.64
Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood (2007) 2.64
A new role for Nogo as a regulator of vascular remodeling. Nat Med (2004) 2.63
Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A (2010) 2.62
A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc (2007) 2.59
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol (2006) 2.58
Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease. Cell Metab (2007) 2.53
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 2.53
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A (2012) 2.50
Direct evidence for the role of caveolin-1 and caveolae in mechanotransduction and remodeling of blood vessels. J Clin Invest (2006) 2.47
Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res (2006) 2.42
Cell proliferation at 122 degrees C and isotopically heavy CH4 production by a hyperthermophilic methanogen under high-pressure cultivation. Proc Natl Acad Sci U S A (2008) 2.41
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2011) 2.40
CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res (2011) 2.39